- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05755347
Assessing Functional Status Needs Via PRO Measures for Pts With Metastatic Breast Cancer
April 9, 2024 updated by: UNC Lineberger Comprehensive Cancer Center
Assessing Functional Status Needs Via Patient-Reported Outcomes Measures in the Pre-treatment Setting With Metastatic Breast Cancer Patients
The purpose of this single-site non-randomized study is to identify areas of need related to functional status and overall health, including nutrition and mental health in subjects with metastatic breast cancer (MBC).
A decline in functional status is observed after breast cancer diagnosis and exacerbated by treatment.
Declining functional status impacts the quality of life and can lead to increased comorbidity burden, hospitalization, and increased mortality.
Functional status is assessed by specific provider-graded scales.
Patient Reported Outcome (PRO) measures may better assess certain aspects of patient health and symptom domains.
Thus, potentially supporting the future implementation of effective prehabilitation strategies.
This study explores whether a PRO-based survey will identify the physical and emotional health and the social and financial status of patients newly diagnosed with MBC.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
50
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Stephen Rego
- Phone Number: (919) 445-4255
- Email: srego@ad.unc.edu
Study Contact Backup
- Name: Carly Bailey
- Email: carly_bailey@med.unc.edu
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Lineberger Comphrehensive Cancer Center at University of North Carolina at Chapel Hill
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Sampling Method
Non-Probability Sample
Study Population
Subject with metastatic breast cancer receive treatment at the University of North Carolina, Lineberger Comprehensive Cancer Center.
Description
In order to participate in this study a subject must meet all of the eligibility criteria outlined below.
Inclusion Criteria:
- Written informed consent was obtained from participants in the study and HIPAA authorization for release of personal health information.
- Subject is willing and able to comply with study procedures based on the judgment of the investigator or protocol designee.
- Age ≥ 18 years at the time of consent.
- Recent diagnosis of new metastatic breast cancer at time of screening.
Exclusion Criteria:
- Exclusion Criteria
- Inability to read or speak English.
- Dementia, altered mental status, or any psychiatric condition as determined by clinical or study team that would prohibit the understanding or rendering of informed consent.
- Current incarceration.
- Subject has already received treatment for metastatic breast cancer prior to screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Single Arm
Subjects with metastatic breast carcinoma have been receiving treatment at the study center and responding to survey questionnaires.
|
Patient-reported outcome survey will be offered at baseline.
Patient-reported outcome survey will be offered at baseline.
Patient-reported outcome survey will be offered at baseline.
Patient-reported outcome survey will be offered at baseline.
Patient-reported outcome survey will be offered at baseline.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Physical activity levels
Time Frame: Baseline
|
Physical activity levels will be measured using the Godin Leisure-Time Exercise Questionnaire.
Godin Leisure-Time Exercise Questionnaire has 3 dichotomous questions, answers will be "yes" or "no".
There will be reason questions if the answer is no.
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acceptability of survey
Time Frame: Baseline
|
Acceptability of survey to subjects will be measured by the percentage of eligible patients who complete the survey.
|
Baseline
|
Health-related quality of life - FACT-G
Time Frame: Baseline
|
Health-related quality of life will be measured by Functional Assessment of Cancer Therapy (FACT-G) which is a survey assessing physical, emotional, and functional well-being on a Likert-type scale.
higher scores demonstrating higher health-related quality of life, from 0 to 4. Higher scores represent better QOL.
|
Baseline
|
Health-related quality of life - PROMIS
Time Frame: Baseline
|
The patient-Reported Outcomes Measurement Information System (PROMIS) survey will assess physical function, fatigue, and social participation.
This survey was designed for cancer rehabilitation needs.
It asks patients on a Likert-type scale about their ability to perform mobility and activities of daily living tasks along with the frequency of fatigue and ability to participate in vocational and avocational activities.
|
Baseline
|
Diet quality
Time Frame: Baseline
|
The diet quality will be measured using a modified version of the Rapid Eating Assessment for Participants (REAP-S) survey will assess diet and nutrition quality.
For the general population, a score of 32 or higher determines a high-quality/desirable diet.
The survey asks about the intake of nutrients including vegetables/fruit, whole grains, types of fat, calcium-rich foods, and others.
Responses usually/often receive 1 point, sometimes receive 2 points, and rarely/do not apply to receive 3 points.
|
Baseline
|
the percentage of subjects referred
Time Frame: Baseline
|
the percentage of subjects referred will be defined as subjects who have been referred to or used Lineberger Comprehensive Cancer Center supportive services for patients Referral rates will be reported for an array of the University of North Carolina Lineberger supportive services by questionnaire.
|
Baseline
|
Barriers to access exercise
Time Frame: Baseline
|
Barriers to accessing exercise will be evaluated by questionnaire.
|
Baseline
|
health-related opinions
Time Frame: Baseline
|
Health-related opinions regarding prehabilitation interventions will be assessed by questionnaire which includes open-ended questions.
|
Baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Sasha Knowlton, MD, UNC Lineberger Comprehensive Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 17, 2023
Primary Completion (Actual)
February 5, 2024
Study Completion (Actual)
February 5, 2024
Study Registration Dates
First Submitted
February 22, 2023
First Submitted That Met QC Criteria
February 22, 2023
First Posted (Actual)
March 6, 2023
Study Record Updates
Last Update Posted (Actual)
April 11, 2024
Last Update Submitted That Met QC Criteria
April 9, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LCCC2241
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on General health survey questionnaires
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHead and Neck CancerUnited States
-
M.D. Anderson Cancer CenterCompleted
-
M.D. Anderson Cancer CenterCompleted
-
M.D. Anderson Cancer CenterUnknown
-
M.D. Anderson Cancer CenterCompleted
-
Thai Red Cross AIDS Research CentreRecruiting
-
CochlearQbD Clinical; Suministros Hospitalarios Medical GroupCompletedChronic Otitis MediaSpain, France, Germany
-
Children's Hospital Medical Center, CincinnatiTexas A&M University; Children's National Research Institute; Baylor UniversityCompletedType 1 Diabetes MellitusUnited States
-
M.D. Anderson Cancer CenterCompleted